Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Susan O’Brien(The University of Texas MD Anderson Cancer Center), Robert Tarnai(Pharmaceutical Product Development (United States)), Jeffrey L. Jorgensen(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Deborah A. Thomas(Washington University in St. Louis), Stefan Faderl(Jazz Pharmaceuticals (United States)), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Richard Champlin(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Monica Kwari(The University of Texas MD Anderson Cancer Center), Anjali S. Advani(Cleveland Clinic), Sa A. Wang(Beijing Institute of Technology), Mary Beth Rios(The University of Texas MD Anderson Cancer Center), Michael Rytting(The University of Texas MD Anderson Cancer Center), Sergernne York(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(Augusta University Health)
Cited by 411
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k